Vestal Point Capital, LP Achilles Therapeutics PLC Put Options Transaction History
Vestal Point Capital, LP
- $1.21 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ACHL
# of Institutions
34Shares Held
23.5MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$9.09 Million9.24% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$1.96 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.32 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.18 Million0.24% of portfolio
-
Stem Point Capital LP New York, NY1.39MShares$1.14 Million0.46% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $33.4M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...